• http://www.revobiologics.com/sites/default/files/_rotation-images/slide-3-new.jpg

    Making a Real Difference

    With an unwavering commitment to patients with rare diseases, rEVO Biologics is moving healthcare forward.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/rotation_3.jpg

    Solutions for Rare Diseases

    rEVO Biologics is a rare disease company delivering on the promise of innovative therapies.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/slide-2-new.jpg

    Delivering Innovative Therapies

    Through groundbreaking technology, rEVO Biologics is changing the way rare diseases are treated.

News Releases

rEVO Biologics, Inc. Supports National Preeclampsia Awareness...

Thursday, May 14, 2015

FRAMINGHAM, Mass., May 14, 2015 — rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced their support to raise awareness of preeclampsia during the third annual National Preeclampsia Awareness Month in May. The Preeclampsia Foundation secured this nationwide designation to educate individuals and organizations about the effects of preeclampsia and the importance of prenatal and postpartum care and education.

Preeclampsia is a leading cause of death in pregnant women.  It is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, often the kidneys. It occurs in approximately five to eight percent of all pregnancies and typically occurs after the 20th week of pregnancy. Early onset preeclampsia is a severe form that arises between 23 and 34 weeks gestation. The cause of preeclampsia is unknown, but the number of cases is growing rapidly. At present, delivery of the baby is...

Contact Us +